The AG genotype reduced the risk of hepatoblastoma compared to the GG genotype (adjusted OR = 0.58, 95% CI = 0.42‐0.80, P = .0009), while H19 rs217727 polymorphism was associated with significantly lower hepatoblastoma risk (dominant model: adjusted OR = 0.58, 95% CI = 0.43‐0.79, P = .0004). This evidence concerns the gene H19 and hepatoblastoma.